Research and Development Expenses: $39.4 million for the fiscal year ended March 31, 2025, up from $20 million the previous year. General and Administrative Expenses: $17.1 million for the fiscal year ended March 31, 2025, compared to $14.1 million the previous year. Net Loss: $51.4 million for the fiscal year ended March 31, 2025, compared
Instil Bio Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS,
“The first quarter of 2025 showed strong execution of our strategic initiatives and demonstrates that we are steering Stem in the right long-term direction,” said Doran Hole, Chief Financial Officer and Executive Vice President of Stem. “We achieved strong GAAP and non-GAAP gross margins, driven by the strength of our high-margin software, services, and edge
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company
Generation Bio Co. – Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA – Lead target and portfolio strategy to be announced mid-2025 – Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May
Revenue: $139 million in Q1 2025, representing 28% growth over Q1 2024. Crysvita Revenue: $103 million, with 25% growth over 2024; $41 million from North America, $55 million from Latin America and Turkey, $7 million from Europe. Dojolvi Revenue: $17 million, consistent with steady growth. Evkeeza Revenue: $11 million, with increasing demand following launches outside
CAMPBELL, Calif., May 06, 2025–(BUSINESS WIRE)–Tigo Energy, Inc. (“Tigo”, or the “Company”) (NASDAQ: TYGO), a leading provider of intelligent solar and energy storage solutions, today reported unaudited financial results for the first quarter ended March 31, 2025, financial guidance for the second quarter ending June 30, 2025 and a full year 2025 outlook. Recent Financial
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filing Successful FDA Type
Revenue: $73.5 million in Q1 2025, compared to $76.2 million in Q4 2024. GAAP Gross Margin: 38.6%. Non-GAAP Gross Margin: 41%. GAAP Operating Expenses: $48.1 million in Q1 2025. Non-GAAP Operating Expenses: $37.4 million. Adjusted EBITDA Loss: $2.9 million in Q1 2025. Non-GAAP Income: $1.2 million, or $0.04 per share. Stock Repurchase: 646,000 shares repurchased
Research and Development Expenses: $13.4 million for Q1 2025, down from $19.8 million in Q1 2024. General Administrative Expenses: $7 million for Q1 2025, down from $10.1 million in Q1 2024. Net Loss: $17.7 million for Q1 2025, compared to $26.9 million in Q1 2024. Cash, Cash Equivalents, and Marketable Securities: $226.6 million as of